Naturally occurring and synthetic bioactive molecules as novel non-nucleoside HBV inhibitors.
Hepatitis B virus (HBV) infection is a severe health problem all over the world. However, there is still no satisfactory anti-HBV therapeutic strategy. Currently, promising alternative approaches toward the control of HBV infection include the development of structurally novel and more potent inhibitors obtained from natural products and structural modifications of synthetic molecules as seen in many cases. In this review, we will focus our interest on representative naturally occurring and synthetic small molecule non-nucleoside inhibitors with high anti-HBV potency and potential for future therapeutic regimens to combat HBV infection.
Zhan
Peng
P
Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, PR China.
Jiang
Xuemei
X
Liu
Xinyong
X
D000470:Alkaloids / Q000737:chemistry / Q000627:therapeutic use; D000998:Antiviral Agents / Q000737:chemistry* / Q000627:therapeutic use; D001688:Biological Products / Q000737:chemistry / Q000627:therapeutic use; D044950:Flavanones / Q000737:chemistry / Q000627:therapeutic use; D006509:Hepatitis B / Q000188:drug therapy*; D006571:Heterocyclic Compounds / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D017705:Lignans / Q000737:chemistry / Q000627:therapeutic use; D013729:Terpenes / Q000737:chemistry / Q000627:therapeutic use
D000470:Alkaloids; D000998:Antiviral Agents; D001688:Biological Products; D044950:Flavanones; D006571:Heterocyclic Compounds; D017705:Lignans; D013729:Terpenes; C505802:helioxanthin